GlaxoSmithKline has appointed Iain Mackay as its new Chief Financial Officer (CFO), marking another high-level appointment under new CEO Emma Walmsley. He joins from HSBC, where he has been Group Finance Director for the last 8 years.
Iain will join the company on 14 Janurary 2019 and will also be appointed as an Executive Director to the GSK Board. GSK announced in May that its current CFO, Simon Dingemans, is to retire in May 2019.
A chartered accountant, Iain has worked in Asia, the US and Europe and before HSBC was at General Electric, Schlumberger Dowell and Price Waterhouse. He is a trustee of the British Heart Foundation and a member of the Court of the University of Aberdeen.
GSK’s CEO Emma Walmsley said: “I’m delighted to welcome Iain to GSK. As a proven CFO of a complex, regulated global organisation, he brings tremendous finance experience and will be a great addition to the team. He is a strong leader with a track record of driving cost, cash and capital allocation discipline to deliver strategy. These capabilities will be vital as we continue to implement our Innovation, Performance and Trust priorities for the benefit of patients and shareholders.”
Since taking over as CEO in April last year, Walmsley has appointed Luke Miels as head of pharmaceuticals and Hal Barron as head of drug research, as well as finding a new head of digital operations in Karenann Terrell.
Philip Hampton, Chairman, GSK said: “On behalf of the Board I welcome Iain to GSK. His experience in different sectors and in complex, regulated environments will be valuable to the Board and I look forward to his contributions.”
Simon Dingemans will continue to be accountable as CFO for GSK’s financial governance through March 2019. There will be a transition period from 14 January when Iain is CFO Designate, with him taking formal accountability as CFO from 1 April.
By: George Underwood
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.